https://www.selleckchem.com/pr....oducts/tabersonine.h
MUAC after 4 wk was noninferior (Δ -0.1mm; 95% CI -0.05, 0.03; inferiority rejected =0.008). Rates of weight gain and MUAC gain were the same in the optimized-dose and standard-dose groups, whereas the rate of length gain was slower in the optimized-dose cohort. Time-to-relapse to SAM or death was not different (HR 1.05; =0.71). This study supports the practice of treating children with SAM who have recovered to meet criteria for MAM with a reduced and fixed-dose regimen of RUTF. The results also raise the question of whether this s
Like
Comment
Share
